Ji (Jessica) Son (@JessSonMD) profile picture

Ji (Jessica) Son

@JessSonMD

#GynOnc fellow at @MDAndersonNews via @dartmouth @CWRUSOM and @CleObGynTracks. Views are my own.

Joined August 2020
  • Tweets49
  • Following109
  • Followers140
Our. Fellows. Rock!!! @MDAndersonNews GYN ONC fellows presenting novel #ClinicalTrials at #ASCO25 @JessSonMD - phase 1 trial of etiglimab and nivolimab in clear cell #OvarianCancer
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
1
5
18
1,258
Thank you for highlighting our work, and thank you to our patients who participated! Honored to receive the Eisai endowed merit award with mentorship from @ShannonWestin. @ASCO @ConquerCancerFd @EisaiUS
UT MD Anderson (@UTMDAnderson) profile pictureUT MD Anderson
@UTMDAnderson1 Jun 2025
Replying to @UTMDAnderson @ASCO @Jeremy_Ramdial
Our fellow @JessSonMD presented promising results for a heavily pretreated population from the EON Phase II trial of etigilimab and nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer. @ShannonWestin @ASCO #ASCO25 #EndCancer
Dr. Jess Son in front of her poster at ASCO 2025

ALT Dr. Jess Son in front of her poster at ASCO 2025

1
127
An inspirational message @Frumovitz @MDAndersonNews, we applaud your bravery, courage, strength, and passion always 💜 #SGOMtg #FrumoFighters – at San Diego, CA
Image from Nicole D. Fleming MD (@nicoleflemingmd)
2
13
2
70
5,613
Fine tuning these superstar’s concepts with clinical trial design experts today. @emilydressler stastistician extraordinaire is AMAZING!! ⁩ Your trainees are in great hands ⁦@ShannonWestin⁩ ⁦@Neil_Iyengar⁩ ⁦@amandanfader⁩ ⁦@AACR⁩ ⁦@ASCO⁩ #MCCR23
Image from Nathalie Mckenzie, MD MSPH (@NathalieMckenz3)
Image from Nathalie Mckenzie, MD MSPH (@NathalieMckenz3)
Image from Nathalie Mckenzie, MD MSPH (@NathalieMckenz3)
3
4
3
24
6,061
Y’all, meet all my new friends who happen to also be the future of clinical research in oncology & hematology!!! @ASCO @AACR #MCCR23 #unVAILed
Image from Shruti Patel, MD (@ShrutiPatelMD)
3
13
117
14,148
Ji (Jessica) Son retweeted
Peter WT Pisters, MD (@ppisters) profile picture
Peter WT Pisters, MD@ppisters7 Jul 2023
Our Chief Patient Experience Officer Dr. Michael Frumovitz's story reflects @MDAndersonNews' profound impact based on his personal journey as a patient. Thank you, @Frumovitz, for your honesty, for your determination and for your unwavering dedication to our patients. #EndCancer
UT MD Anderson (@UTMDAnderson) profile pictureUT MD Anderson
@UTMDAnderson6 Jul 2023
“I have more understanding of what they are going through now than I ever did before,” says our Chief Patient Experience Officer Dr. Michael Frumovitz. Learn how his diagnosis has shaped his perspective: fal.cn/3zGLn @Frumovitz #PancreaticCancer #EndCancer
14
58
5,704
Beating the Texas 🔥 with #teambuilding and #tacos with our amazing @MDAndersonNews Gyn Onc fellows and graduates! @jahow514 @HanTCun @NiteckiRoni @aaronshafer99
Image from Nicole D. Fleming MD (@nicoleflemingmd)
4
32
1,528
🤯Exciting data for @gyncsm presented at #ASCO23 DT session by @MDAndersonNews Dr. Funda Meric-Bernstam! 🎯DESTINY Pan-Cancer demonstrated activity of T-DXd (#AntibodyDrugConjugate) across multiple #HER2 ➕tumors 👍especially #EndometrialCancer #CervicalCancer & #OvarianCancer
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
1
20
3
63
12,947
Ji (Jessica) Son retweeted
David S. Hong MD (@DavidHongMD) profile picture
David S. Hong MD@DavidHongMD6 Jun 2023
Our Amazing Dr Son! Watch her! She will become a future superstar! – at Chicago, IL
Ji (Jessica) Son (@JessSonMD) profile pictureJi (Jessica) Son@JessSonMD6 Jun 2023
Thank you @ShannonWestin and @DavidHongMD for your mentorship and @ConquerCancerFd and @EisaiGlobalOnc for the endowed merit award! We are honored to share our work on RAS mutation in gyn cancer patients, which may help patient selection and future trial design #ASCO23 #gyncsm
2
9
1,016
💡@jahow514 presented an intriguing trial in progress in collaboration with mentor @AmirJazaeri exploring use of lenvatinib and pembrolizumab in recurrent #OvarianCancer #ASCO23 #gyncsm #ImmunoOnc
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
2
5
12
1,101
🤔 @Naomi_AdjeiMD presented thought provoking data regarding uptake of upfront maintenance therapy in #OvarianCancer - understanding the disparities in use of #PARPi +/- bevacizumab is essential to improve outcomes for our patients #ASCO23 #gyncsm
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
2
6
12
1,152
🔪 @AnneKniselyMD demonstrated that identification of #MRD at second look laparoscopy in #OvarianCancer is associated with worse survival outcomes #ASCO23 #gyncsm
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
6
12
1,042
#ASCO23🧵 highlighting the amazing work by our @MDAndersonNews #oncsurgery #GynOnc fellows. 🙌These trainees are going to change the #gyncsm world and #endcancer
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
2
5
34
2,201
Thank you @ShannonWestin and @DavidHongMD for your mentorship and @ConquerCancerFd and @EisaiGlobalOnc for the endowed merit award! We are honored to share our work on RAS mutation in gyn cancer patients, which may help patient selection and future trial design #ASCO23 #gyncsm
Shannon Westin, MD, MPH, FASCO (@ShannonWestin) profile pictureShannon Westin, MD, MPH, FASCO@ShannonWestin6 Jun 2023
Replying to @ShannonWestin
🧐 @JessSonMD identified #gyncsm patients that might benefit from RAS/RAF inhibitors based on presence of aberrations in the pathway #ASCO23 #cagenome
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
1
5
1
20
3,348
👀this is the FIRST TRIAL to show overall survival benefit in platinum resistant #OvarianCancer. 🙌Standard of care is clear! 🧐Get the FOLR1 testing and identify the patients that will benefit from mirvetuximab #ASCO23 #gyncsm
Eleonora Teplinsky, MD, FASCO (@drteplinsky) profile pictureEleonora Teplinsky, MD, FASCO
@drteplinsky4 Jun 2023
🚨Amazing to see ⬆️ in overall survival for mirvetixumab in FOLR1 positive platinum resistant #ovariancancer. Absolutely new standard of care!! 👏 #gyncsm #ASCO23
Image from Eleonora Teplinsky, MD, FASCO (@drteplinsky)
Image from Eleonora Teplinsky, MD, FASCO (@drteplinsky)
Image from Eleonora Teplinsky, MD, FASCO (@drteplinsky)
Image from Eleonora Teplinsky, MD, FASCO (@drteplinsky)
34
5
91
18,118
Ji (Jessica) Son retweeted
rcoledude (@rcoledude) profile picture
rcoledude@rcoledude4 Jun 2023
#ASCO2023 wow- OS data confirms lasting benefit! New results from the MIRASOL trial. Congratulations Dr Moore. So rare to see PFS and OS Hazard Ratio of the same magnitude in gynecological cancer. #gyncsm
Image from rcoledude (@rcoledude)
2
17
3
63
6,117
Ji (Jessica) Son retweeted
Dr.Monica Avila (@MAvilaMD) profile picture
Dr.Monica Avila@MAvilaMD3 Jun 2023
3rd #ADC on the @US_FDA trajectory??Promising Phase 1 data of Luvelta targeting FOLRalpha platinum-resistant ovarian cancer were randomized in 1:1 to lower/higher dosing with ORR of 31.7% in FOLR agnostic population and 37.5% in TPS>25% #MoffittASCO23 #ASCO23 @MoffittNews
Image from Dr.Monica Avila (@MAvilaMD)
Image from Dr.Monica Avila (@MAvilaMD)
Image from Dr.Monica Avila (@MAvilaMD)
6
1
16
5,124
#SHAPE trial 🌟simple hysterectomy for early stage #cervicalcancer 🌟simple vs radical hyst 1A2-1B1 (<2cm) confirms non-inferiority of a 3yr pelvic recurrence rate and secondary endpts PFS/OS are met @OncoAlert @GynMe4 @IJGConline – at Oslo, Norway
Glauco Baiocchi (@glaucobaiocchi) profile pictureGlauco Baiocchi@glaucobaiocchi2 Jun 2023
Happy to see in person Dr Plante presenting SHAPE trial. Huge impact for women with cervical cancer in a surgical trial! Congrats to all investigators!! @ASCO @IGCSociety @ESGO_society @SGO_org @acccancercenter @br_gynoncgroup
Image from Glauco Baiocchi (@glaucobaiocchi)
1
9
2
42
5,330
🚨Another practice-changing study at #ASCO23 🌟DUO-O/@GOG 3025 demonstrates improved progression free survival in pts w/ HR deficient AND proficient advanced stage #OvarianCancer treated with durvalumab + olaparib + bevacizumab #gyncsm #ImmunoOnc
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
Image from Shannon Westin, MD, MPH, FASCO (@ShannonWestin)
5
39
7
89
42,628
Hot off the presses!🔥📰 @NCCN Ovarian Cancer Guidelines endorse oxaliplatin-based regimens like docetaxel/oxali/bevacizumab (Teaco trial) in special circumstances (i.e. chemo shortages💉). Thank u Dr. Deb Armstrong & team for supporting the @SGO_org @GYNCancer @GOG @ASCO recs.👏
2
18
1
40
3,144
Load more